Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
MorphoSys AG (MUC:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its management will give company presentations at five investor conferences in September 2008.
Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG, will present an overview of the Company at the following conferences:
Sal. Oppenheim's 3rd European Healthcare Investors Conference Date: Wednesday, September 3, 2008 Time: 12.20 pm CET (11.20 am BST / 06.20 am EDT) Venue: Villa Kennedy, Frankfurt/Main, Germany
Newsmakers in the Biotech Industry Conference Date: Thursday, September 4, 2008 Time: 09.30 am EDT (03.30 pm CET / 02.30 pm BST) Venue: Millennium Broadway Hotel, New York City, USA
Danske Markets Equities' and ESN's Antibody Seminar Date: Tuesday, September 30, 2008 Venue: Danske Bank, Stockholm, Sweden
Dave Lemus, Chief Financial Officer of MorphoSys AG, will present an overview of the Company at the following conferences:
2nd Goldman Sachs Biotech Symposium Date: Friday, September 5, 2008 Venue: Goldman Sachs, London, UK
8th Annual Biotech in Europe Investor Forum Date: Tuesday, September 23, 2008 Venue: Swissôtel, Zurich, Switzerland
"Our invitation to the Newsmakers conference in New York illustrates the increasing investor interest in MorphoSys", commented Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations of MorphoSys AG.
Live and archived webcasts of the presentations will be available at www.morphosys.com.
For further information please contact: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj, Manager Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-454, brkulj@morphosys.com
About MorphoSys: MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford). For further information please visit http://www.morphosys.com/
HuCAL(R), HuCAL GOLD(R) and RapMAT(R) are registered trademarks of MorphoSys AG
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
